Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 17
4 116
3 131
2 41
1 23
NEB 4
Curative setting
A 46
C 3
NEB 1
ESMO-MCBS Scores by tumour type
Non-curative setting
Breast Cancer 38
Central Nervous System Malignancies 0
Endocrine Tumours 20
Gastrointestinal Cancers 62
Genitourinary Cancers 60
Gynaecological Malignancies 34
Head and neck cancer 12
Refractory NTRK fusion-positive cancers 2
Sarcoma 9
Skin Cancers 27
TMB-H solid tumours 1
Thoracic Malignancies 66
dMMR/MSI-H solid tumour 1
Curative setting
Breast Cancer 8
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 15
Genitourinary Cancers 3
Gynaecological Malignancies 0
Head and neck cancer 1
Refractory NTRK fusion-positive cancers 0
Sarcoma 2
Skin Cancers 12
TMB-H solid tumours 0
Thoracic Malignancies 4
dMMR/MSI-H solid tumour 0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Niraparib - Placebo Maintenance treatment for high grade ovarian, fallopian tube or peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based ChT PRIMA/ENGOT-OV26/COG-3012
    Gynaecological Malignancies
    		 Ovarian, fallopian tubes and peritoneum cancer HRD+ PRIMA/ENGOT-OV26/COG-3012

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Olaparib Bevacizumab Placebo plus bevacizumab Maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability PAOLA-1
    Gynaecological Malignancies
    		 High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer BRCA mutation PAOLA-1

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Olaparib Bevacizumab Placebo plus bevacizumab Maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability PAOLA-1
    Gynaecological Malignancies
    		 High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer HRD+ BRCA-WT PAOLA-1

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Avelumab - Single arm Adult patients with metastatic Merkel cell carcinoma (MCC) JAVELIN Merkel 200 (Part A - pretreated patients)
    Skin Cancers
    		 Merkel cell carcinoma - JAVELIN Merkel 200 (Part A - pretreated patients)

    4

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      4
    Nivo/Ipi (nivolumab and ipilimumab) - ChT with cisplatin or carboplatin plus pemetrexed First-line treatment for adult patients with unresectable malignant pleural mesothelioma. CheckMate743
    Thoracic Malignancies
    		 Pleural mesothelioma - CheckMate743

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      3
    Nivo/Ipi (nivolumab and ipilimumab) - Single arm (Phase II) Patients with HCC who have been previously treated with sorafenib CheckMate 040
    Gastrointestinal Cancers
    		 Hepatobiliary Cancers - Hepatocellular Carcinoma - CheckMate 040

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Tazemetostat - Single arm (Phase II) Treatment for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection EZH-202
    Sarcoma
    		 Epithelioid INI1-negative EZH-202

    1

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      1
    Tepotinib - Single arm Treatment for patients with NSCLC harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping following prior treatment with immunotherapy and/or platinum-based ChT VISION
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer METex14 skipping VISION

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Cemiplimab - Platinum based ChT (Crossover allowed) First-line locally advanced NSCLC who are not candidates for definitive chemoradiation or metastatic NSCLC EMPOWER-Lung 1
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer PD-L1>50% negative EGFR, ALK or ROS1 EMPOWER-Lung 1

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Cabozantinib - Sunitinib First-line treatment of adult patients with intermediate or poor risk advanced RCC CABOSUN
    Genitourinary Cancers
    		 Renal cell cancer - CABOSUN

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Dostarlimab - Single arm (Phase I) Treatment of adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer that have progressed on or following prior treatment with a platinum-containing regimen GARNET
    Gynaecological Malignancies
    		 Endometrial Cancer dMMR or MSI-H GARNET

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Nivo/Ipi (nivolumab and ipilimumab) 2 cycles of platinum-based ChT Chemotherapy First line treatment of mNSCLC with no sensitising EGFR mutation or ALK translocation CheckMate-9LA
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - CheckMate-9LA

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    5-FU/LV (5-fluorouracil + leucovorin) - Lomustine (MeCCNU) + vincristine + 5-FU Patients with Dukes' stage B and C colon cancer NSABP C-03
    Gastrointestinal Cancers
    		 Colon Cancer - NSABP C-03

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    5-FU (fluorouracil) Folinic acid Observation Patients with surgically resected colon cancer in Dukes' stage C
    Gastrointestinal Cancers
    		 Colon Cancer - -

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    5-FU/LV (fluorouracil + leucovorin) - Observation High-risk stage II or stage III colon cancer NCCTG 874651
    Gastrointestinal Cancers
    		 Colon Cancer - NCCTG 874651

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    5-FU (fluorouracil) Folinic acid Surgery alone Patients with resectable Dukes B and C (AJCC/UICC Stage II and Stage III) colon carcinoma GIVIO-SITAC 01
    Gastrointestinal Cancers
    		 Colon Cancer - GIVIO-SITAC 01

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole) - Surgery alone (Meta-analysis) Patients with stage II and III colon cancer (ITT and age stratified including >70 years)
    Gastrointestinal Cancers
    		 Colon Cancer - -

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole) - Surgery alone (Pooled-analysis) Patients with stage II and III colon cancer
    Gastrointestinal Cancers
    		 Colon Cancer - -

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole) - Surgery alone (Meta-analysis) Patients with resected stage II and III colon cancer
    Gastrointestinal Cancers
    		 Colon Cancer - -

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole) - Surgery alone (Meta-analysis) Patients with resected stage II and III colon cancer
    Gastrointestinal Cancers
    		 Colon Cancer - -

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    5FU/LEV (5-fluorouracil + levamisole) - Levamisole Resected stage III (Dukes stage C) colon cancer Intergroup 0035
    Gastrointestinal Cancers
    		 Colon Cancer - Intergroup 0035

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    Tivozanib - Sorafenib Adult patients with relapsed or refractory advanced RCC following ≥2 prior systemic therapies TIVO-3
    Genitourinary Cancers
    		 Renal cell cancer - TIVO-3

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Enzalutamide ADT (androgen deprivation therapy) Placebo + ADT For the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy ARCHES
    Genitourinary Cancers
    		 Prostate cancer - ARCHES

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Lorlatinib - Crizotinib Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive (NSCLC) previously not treated with an ALK inhibitor CROWN
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ALK+ CROWN

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      4
    Sacituzumab govitecan-hziy - Physician’s choice of single agent ChT Treatment for adult patients with metastatic triple-negative breast cancer who received at least two or more prior therapies, at least one of them for advanced disease ASCENT
    Breast Cancer
    		 Breast Cancer Triple-negative ASCENT

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Nivolumab Cabozantinib Sunitinib First-line treatment of adult patients with advanced RCC CheckMate-9ER
    Genitourinary Cancers
    		 Renal cell cancer - CheckMate-9ER

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      1
    Atezolizumab - Single arm (Phase II) Single-arm study of atezolizumab in patients with locally advanced or metastatic urothelial bladder cancer IMvigor210 (Cohort 2)
    Genitourinary Cancers
    		 Urothelial Carcinoma - IMvigor210 (Cohort 2)

    1

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      1
    Enfortumab vedotin - Single arm (Phase II) Patients with locally advanced or metastatic UC who are ineligible for cisplatin-containing ChT and have previously received ≥1 prior lines of therapy EV-201 - Cohort 2
    Genitourinary Cancers
    		 Urothelial Carcinoma - EV-201 - Cohort 2

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Erdafitinib - Single arm (Phase II) Locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations and disease progression during/after ≥1 prior platinum-containing ChT BLC2001
    Genitourinary Cancers
    		 Urothelial Carcinoma FGFR3 or FGFR2 genetic alterations BLC2001

    1

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      1
    Pembrolizumab - Single arm (Phase II) Locally advanced or metastatic UC in adults who are not eligible for cisplatin-containing ChT and whose tumours express PD-L1 with a CPS ≥10 MK-03475-052/KEYNOTE-052
    Genitourinary Cancers
    		 Urothelial Carcinoma PD-L1 CPS ≥10% MK-03475-052/KEYNOTE-052

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.